Ipca Laboratories - Two For One Share Stock Split: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
The Ipca Laboratories Ltd.'s stock has been sub-divided from one existing equity share of Rs 2 each face value into two equity shares of Rs 1 each face value. The record date for the same is January 11, 2022 while the ex-date for the same is today i.e. January 10, 2022.
Consequently, Ipca Lab’s share price has dropped to ~Rs 1099/share from ~Rs 2200/share. The company has recently acquired Lyka Labs, which can be value accretive and is likely to benefit Ipca Labs Ltd. to enter into lucrative lyophilised injectables business in India and rest of world markets.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.